Polysomy 17 and HER-2 Amplification: True, True, and Unrelated

被引：26

作者：

Rosenberg, Carol L. ^{[1
]}

机构：

[1] Boston Univ, Med Ctr, Dept Med, Boston, MA 02215 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 30期

关键词：

D O I：

10.1200/JCO.2008.17.2684

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：4856 / 4858

页数：3

共 31 条

[1] Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution [J].

Allred, D. Craig ;

Wu, Yun ;

Mao, Sufeng ;

Nagtegaal, Iris D. ;

Lee, Sangjun ;

Perou, Charles M. ;

Mohsin, Syed K. ;

O'Connell, Peter ;

Tsimelzon, Anna ;

Medina, Dan .

CLINICAL CANCER RESEARCH, 2008, 14 (02) :370-378

[2]

[Anonymous], J CLIN ONCOL S

[3] Vaccination against HER-2/neu oncogenic protein [J].

Bernhard, H ;

Salazar, L ;

Schiffman, K ;

Smorlesi, A ;

Schmidt, B ;

Knutson, KL ;

Disis, ML .

[4]

Bose S, 2001, Breast J, V7, P337, DOI 10.1046/j.1524-4741.2001.21018.x

[5] Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion [J].

Czerniecki, Brian J. ;

Koski, Gary K. ;

Koldovsky, Ursula ;

Xu, Shuwen ;

Cohen, Peter A. ;

Mick, Rosemarie ;

Nisenbaum, Harvey ;

Pasha, Terry ;

Xu, Min ;

Fox, Kevin R. ;

Weinstein, Susan ;

Orel, Susan G. ;

Vonderheide, Robert ;

Coukos, George ;

DeMichele, Angela ;

Araujo, Louis ;

Spitz, Francis R. ;

Rosen, Mark ;

Levine, Bruce L. ;

June, Carl ;

Zhang, Paul J. .

CANCER RESEARCH, 2007, 67 (04) :1842-1852

[6] Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer [J].

Dal Lago, Lissandra ;

Durbecq, Virginie ;

Desmedt, Christine ;

Salgado, Roberto ;

Verjat, Thibault ;

Lespagnard, Laurence ;

Ma, Yan ;

Veys, Isabelle ;

Di Leo, Angelo ;

Sotiriou, Christos ;

Piccart, Martine ;

Larsimont, Denis .

MOLECULAR CANCER THERAPEUTICS, 2006, 5 (10) :2572-2579

[7] Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines [J].

Disis, ML ;

Gooley, TA ;

Rinn, K ;

Davis, D ;

Piepkorn, M ;

Cheever, MA ;

Knutson, KL ;

Schiffman, K .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (11) :2624-2632

[8] The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast - A fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study [J].

Downs-Kelly, E ;

Yoder, BJ ;

Stoler, M ;

Tubbs, RR ;

Skacel, M ;

Grogan, T ;

Roche, P ;

Hicks, DG .

AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2005, 29 (09) :1221-1227

[9] CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer [J].

Esteva, Francisco J. ;

Wang, Jing ;

Lin, Feng ;

Mejia, Jaime A. ;

Yan, Kai ;

Altundag, Kadri ;

Valero, Vicente ;

Buzdar, Aman U. ;

Hortobagyi, Gabriel N. ;

Symmans, W. Fraser ;

Pusztai, Lajos .

BREAST CANCER RESEARCH, 2007, 9 (06)

[10] Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study:: assessment of test sensitivity and impact of chromosome 17 polysomy [J].

Hofmann, M. ;

Stoss, O. ;

Gaiser, T. ;

Kneitz, H. ;

Heinmoeller, P. ;

Gutjahr, T. ;

Kaufmann, M. ;

Henkel, T. ;

Rueschoff, J. .

JOURNAL OF CLINICAL PATHOLOGY, 2008, 61 (01) :89-94

← 1 2 3 4 →